이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

척수 손상 및 제2형 당뇨병 환자에서 GLP-1R 작용제 치료의 혈당 및 체중 감소 효과

2026년 10월 1일 업데이트: Marzieh Salehi

It is not known whether a new diabetes drug, semaglutide, is an effective treatment for type 2 diabetes for persons with spinal cord injury (SCI), a population at higher risk for this condition. Therefore, this study looks at the effect of semaglutide on glucose levels in the body and other information about type 2 diabetes and obesity.

연구 개요

상태

모병

정황

개입 / 치료

상세 설명

This study consists of 7-9 in-person visits and 9-10 phone visits, and participants will be randomized to either semaglutide or placebo for 24 weeks. The participants first visit, will include review of medical history and performance of standard tests to check the participant's health and eligibility for the study. Before starting any medication, participants will have 2 more visits:

  • a mixed meal tolerance test, to examine their body's response to nutrient ingestion and
  • a glucose clamp study to examine insulin sensitivity. These tests will be scheduled on two separate days. Following the 3 baseline visits, participants will be randomized to either the intervention (once-weekly injection of semaglutide, also known as Ozempic, for 24 weeks) or placebo. During the 24-week intervention participants will receive 9-10 phone calls to discuss their progress and experiences with the interventions and will also be asked to return for a short research visit including interim medical history with or without blood sample collection twice. At the end of 24 weeks, the treatments will be discontinued, and participants will repeat the meal and glucose studies scheduled over two separate days. During participation, fat/lean mass will be measured using DEXA and liver fat mass may be measured using fibroscan. In addition, participants may be asked for a stool sample.

연구 유형

중재적

등록 (추정된)

50

단계

  • 4단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 연락처 백업

연구 장소

    • Texas
      • San Antonio, Texas, 미국, 78229
        • 모병
        • University of Texas Health Science Center at San Antonio
        • 수석 연구원:
          • Marzieh Salehi, MD, MS
        • 연락하다:
        • 연락하다:
      • San Antonio, Texas, 미국, 78207
        • 모병
        • University Health - Texas Diabetic Institute
        • 수석 연구원:
          • Marzieh Salehi, MD, MS
        • 연락하다:
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  1. Male and female subjects aged 18-70 years (inclusive) at screening
  2. More than one year after spinal cord injury
  3. Levels if injury C2-L2 with Asia Impairment Scale A, B, C or D.
  4. Provision of signed and dated written informed consent prior to any study specific procedures
  5. Diagnosed with T2DM with glucose control managed with diet and metformin monotherapy where no significant dose changes (increase or decrease ≥ 50%) have occurred in the three months prior to screening
  6. HbA1c 6.0-9.0% at screening
  7. BMI > 22 kg/m2 at screening
  8. Female subjects of childbearing potential must have a negative pregnancy test at screening and randomization, and must not be lactating
  9. Females of childbearing potential who are sexually active with a non-sterilized male partner must use at least one highly effective method of contraception from screening and must agree to continue using such precautions through to the end of the study. It is strongly recommended for the male partner of a female subject to also use male condom plus spermicide throughout this period. Cessation of contraception after this point should be discussed with a responsible physician. Periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of contraception.

Exclusion Criteria:

  1. History of, or any existing condition that, in the opinion of the investigator, would interfere with evaluation of the investigational product, put the subject at risk, influence the subject's ability to participate or affect the interpretation of the results of the study and/or any subject unable or unwilling to follow study procedures.

  2. Any subject who has received another investigational product as part of a clinical study within the last 30 days or 5 half-lives of the drug (whichever is longer) at the time of screening

  3. Taking mirabegron or other glucose altering medications

  4. Taking steroids within the past 1 year

  5. Significant anemia (hemoglobin<11g/dL)

  6. History of gastric outlet obstruction or chronic diarrhea

  7. History of a chronic neurological illness other than SCI (i.e.; MS, etc)

  8. Any subject who has received any of the following medications within the specified time-frame prior to the start of the study

    • Herbal preparations or drugs licensed for control of body weight or appetite (eg, orlistat, bupropion-naltrexone, phentermine-topiramate, phentermine, lorcaserin) within a year prior to the start of the study
    • Pioglitazone, SGLT2 or DPPIV inhibitors, GLP-1RA within the last 60 days at the time of screening
  9. Severe allergy/hypersensitivity to any of the proposed study treatments, excipients, acetaminophen

  10. Symptoms of acutely decompensated blood glucose control (eg, thirst, polyuria, weight loss), a history of type 1 diabetes mellitus (T1DM) or diabetic ketoacidosis, or if the subject has been treated with daily SC insulin within 90 days prior to screening.

  11. Significant inflammatory bowel disease or other severe disease or surgery affecting the upper GI tract (including weight-reducing surgery and procedures) which could affect the interpretation of safety and tolerability data. Prior history of bariatric surgery is not considered exclusion given the ample evidence of safety of use of GLP-1R therapy in this population.

  12. Acute or chronic pancreatitis

  13. Significant hepatic disease (except for metabolic dysfunction-associated steatohepatitis [MASH] or metabolic dysfunction-associated steatotic liver disease [MASLD]) without portal hypertension or cirrhosis) and/or subjects with any of the following results at screening:

    Aspartate transaminase (AST) ≥ 3 × upper limit of normal (ULN) Alanine transaminase (ALT) ≥ 3 × ULN Total bilirubin ≥ 2 × ULN

  14. Impaired renal function defined as estimated glomerular filtration rate (eGFR) < 45 mL/minute/1.73m2 at screening (GFR estimated according to Modification of Diet in Renal Disease (MDRD) using MDRD Study Equation IDMS-traceable [SI units])

  15. Unstable angina pectoris, myocardial infarction, transient ischemic attack (TIA) or stroke within 3 months prior to screening, or subjects who have undergone percutaneous coronary intervention or a coronary artery bypass graft within the past 6 months or who are due to undergo these procedures at the time of screening

  16. Severe congestive heart failure (New York Heart Association Class III or IV)

  17. Basal calcitonin level > 50 ng/L at screening or history/family history of medullary thyroid carcinoma or multiple endocrine neoplasia

  18. History of neoplastic disease within 5 years prior to screening, except for adequately treated basal cell, squamous cell skin cancer, or in situ cervical cancer

  19. History of HIV infection or other immune compromised disease; and history of organ transplantation

  20. Substance dependence or history of alcohol abuse and/or excess alcohol intake

  21. Patients on ketogenic diet

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위화되지 않음
  • 중재 모델: 병렬 할당
  • 마스킹: 하나의

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: SCI and T2DM Treatment Group

Participants with spinal cord injury (SCI) and type 2 diabetes (T2DM) will be assigned to semaglutide weekly for 24 weeks. Semaglutide administration: once-weekly self-administration of SGT, titrated to a dose of 2 mg/week as per FDA approved guidelines. All subjects will be instructed how to inject and titrate up the dose.

A GLP-1 inhibitor used to control T2DM

다른 이름들:
  • 오젬픽
위약 비교기: SCI and T2DM Placebo Group

Participants with spinal cord injury (SCI) and type 2 diabetes (T2DM) will be assigned to the placebo group and inject normal saline weekly for 24 weeks. All subjects in the placebo group will be instructed how to inject and titrate up the dose to mimic the semaglutide administration to a maximum dose of 2 mg in 12 weeks and then continue for remainder of study.

Saline solution will be administered with the same frequency as semaglutide and participants will be instructed how to use the saline in the same manner as the active drug group.

다른 이름들:
  • 생리 식염수

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Glucose tolerance
기간: Baseline to 24 weeks

The change in the incremental AUC Glucose3h response to meal ingestion

Baseline to 24 weeks
Insulin action
기간: Baseline to 24 weeks

Liver, adipose tissue and muscle insulin sensitivity determined using a two-step euglycemic clamp.

Baseline to 24 weeks

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

협력자

수사관

  • 수석 연구원: Marzieh Salehi, MD, The University of Texas Health Science Center at San Antonio

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2025년 4월 11일

기본 완료 (추정된)

2028년 9월 1일

연구 완료 (추정된)

2029년 3월 1일

연구 등록 날짜

최초 제출

2024년 11월 22일

QC 기준을 충족하는 최초 제출

2024년 11월 22일

처음 게시됨 (실제)

2024년 11월 26일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 5일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 10월 1일

마지막으로 확인됨

2026년 10월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • STUDY00000591
  • R01DK140144-02 (미국 NIH 보조금/계약)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

The shared data will be de-identified according to HIPAA and shared under a repository standard Data Use Agreement (DUA).(e.g., all data will be thoroughly de-identified and will not be traceable to a specific study participant). Plans for archiving and long-term preservation of the data will be implemented, as appropriate.ccess to shared data will be controlled according to the repository policy which requires a request and merit review and will be available according to repository processes. The shared data will be de-identified according to HIPAA and shared under a repository standard Data Use Agreement (DUA).

IPD 공유 기간

Study data will be shared as summary results on ClinicalTrials.gov a year after the primary completion date and full results will be shared at study end after data has been analyzed and published in a peer review journal.

IPD 공유 액세스 기준

The scientific data generated from this study will be shared in the Texas Digital Library

IPD 공유 지원 정보 유형

  • 연구_프로토콜
  • 수액
  • ICF

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

미국에서 제조되어 미국에서 수출되는 제품

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .